Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Research - UniQure went through some interesting de-risking two weeks back with the release of initial data (the first publicly) from Baxter International’s (BAX) Hemophilia B gene therapy program, … Continue Reading
Research - Pharmacyclics (PCYC) has been a long-term idea for us, and a profitable one at that. But since August when I last wrote about PCYC at length, there has been little in the way of headline grabbing developments. T